Delving into the Latest Updates on Nanjing Edcheng Ningxin Pharmaceutical Research and Development Co., Ltd. with Synapse

Overview

Tags

Neoplasms

Respiratory Diseases

Other Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Endocrinology and Metabolic Disease	2
Neoplasms	2
Hemic and Lymphatic Diseases	1
Immune System Diseases	1

Top 5 Drug Type	Count

Small molecule drug	2

Top 5 Target	Count

FGFRs x PDGFR x Tyrosine kinase x VEGFR1 x VEGFR2 x VEGFR3 x c-Kit	1
c-Met(Hepatocyte growth factor receptor)	1

主要目的评价AL8326片单药治疗二线及以上系统性方案治疗后复发或进展的小细胞肺癌患者的总生存期（OS）疗效。次要目的评价AL8326片单药在二线及以上系统性方案治疗后复发或进展的小细胞肺癌患者中的无进展生存期（PFS）和其他有效性指标.

[Translation]

Primary objective To evaluate the overall survival (OS) efficacy of AL8326 tablets as a single agent in patients with small cell lung cancer who have relapsed or progressed after second-line or higher systemic treatment. Secondary objective To evaluate the progression-free survival (PFS) and other efficacy indicators of AL8326 tablets as a single agent in patients with small cell lung cancer who have relapsed or progressed after second-line or higher systemic treatment.

Start Date30 Nov 2023

Sponsor / Collaborator

Hangzhou Edcheng Pharmaceutical Technology Co., Ltd.

[+2]

CTR20244102

/ RecruitingPhase 4

盐酸安罗替尼胶囊治疗晚期甲状腺髓样癌患者的真实世界研究方案

[Translation] Real-world study protocol of anlotinib hydrochloride capsules in the treatment of patients with advanced medullary thyroid cancer

在真实世界中，对比观察组患者（未接受同类药物治疗），评价盐酸安罗替尼胶囊在晚期甲状腺髓样癌患者中的有效性和安全性。

[Translation]

In the real world, the efficacy and safety of anlotinib hydrochloride capsules in patients with advanced medullary thyroid cancer were evaluated by comparing them with patients in the observation group (who did not receive similar drug treatment).

Start Date13 Jun 2023

Sponsor / Collaborator

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

[+1]

CTR20230227

/ RecruitingPhase 1

评估AL2846胶囊在既往TKI治疗失败的碘难治分化型甲状腺癌中有效性和安全性的Ib期临床试验

[Translation] A phase Ib clinical trial to evaluate the efficacy and safety of AL2846 capsules in iodine-refractory differentiated thyroid cancer that has failed previous TKI treatment

主要目的评价AL2846胶囊在既往TKI治疗失败的碘难治分化型甲状腺癌患者中的初步疗效。次要目的评价AL2846胶囊在既往TKI治疗失败的碘难治分化型甲状腺癌患者中的安全性

[Translation]

Primary objective To evaluate the preliminary efficacy of AL2846 capsules in patients with iodine-refractory differentiated thyroid cancer who have failed previous TKI treatment. Secondary objective To evaluate the safety of AL2846 capsules in patients with iodine-refractory differentiated thyroid cancer who have failed previous TKI treatment.

Start Date16 Feb 2023

Sponsor / Collaborator

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

[+1]

100 Clinical Results associated with Nanjing Edcheng Ningxin Pharmaceutical Research and Development Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Nanjing Edcheng Ningxin Pharmaceutical Research and Development Co., Ltd.

Login to view more data

100 Deals associated with Nanjing Edcheng Ningxin Pharmaceutical Research and Development Co., Ltd.

Login to view more data

100 Translational Medicine associated with Nanjing Edcheng Ningxin Pharmaceutical Research and Development Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 02 Feb 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 3 Clinical

2

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Anlotinib Dihydrochloride ( FGFRs x PDGFR x Tyrosine kinase x VEGFR1 x VEGFR2 x VEGFR3 x c-Kit )	Uterine Cervical Cancer More	Phase 3
Vilzemetkib ( c-Met )	Refractory Differentiated Thyroid Gland Carcinoma More	Phase 3